Personalized Detection of CtDNA for Patients with HER2-Positive Metastatic Breast Cancer Who Achieved Durable Response by Anti-HER2 Treatment (HER2 CR)

Enrolling by invitationOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Breast Cancer, MetastaticHER2 + Breast Cancer

Interventions

DRUG

Trastuzumab (Herceptin)

Continuing anti-HER2 treatment

DIAGNOSTIC_TEST

SIgnatera

A personalized, tumor-informed test.

Trial Locations (4)

Natera, San Carlos

Aichi Cancer Center, Nagoya

Nagoya City University, Nagoya

The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo

All Listed Sponsors

lead

Nagoya City University

OTHER